Liang C, et al. - Using two administrative databases from commercial health plans in the United States, researchers conducted a retrospective cohort study, supplemented by a nested case-control study, to compare the incidence of pancreatic and thyroid cancer among users of exenatide [a glucagon-like peptide-1 (GLP-1) receptor agonist] vs other antidiabetic drugs (OADs). Between June 1, 2005, and June 30, 2015, they involved patients with type 2 diabetes who started exenatide or OADs. The cohort study used chart-validated algorithms to identify pancreatic and thyroid cancers. In this large follow-up study, exenatide use was not related to an increased risk of pancreatic or thyroid cancer. These results should be interpreted with caution given the long latency period of the study results, particularly pancreatic cancer, and the relatively short follow-up for many patients.